Pfizer Inc.· PFE

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

• 

  Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

  Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.

  Sep 4, 2026
• 

  AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

  AbbVie has successfully pivoted to new immunology leaders to offset the loss of exclusivity for its top-selling drug. Pfizer is utilizing its robust cash position to acquire oncology assets and replenish its product pipeline.

  Sep 4, 2026
• 

  Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion

  Medicus Pharma Ltd. (NASDAQ:MDCX) secured on Wednesday an exclusive, sublicensable global license from Pfizer Inc. (NYSE:PFE) to develop, manufacture, and commercialize PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin.

  Sep 3, 2026
• 

  Pfizer's Pipeline Strategy Centers on Obesity and Oncology

  PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.

  Sep 3, 2026
• 

  3 Things You Need to Know If You Buy Pfizer Stock Today

  Investors won't start seeing the fruits of Pfizer's current efforts for several more years. A handful of its top-selling drugs will be losing their patent protection in the meantime.

  Sep 3, 2026

• UB

  UBS Reiterates Neutral Rating on Pfizer (PFE)

  UBS· Michael Yee· $27.00
  May 27, 2026
• WR

  Pfizer price target raised to $26 from $25 at Wolfe Research

  Wolfe Research· Alexandria Hammond· $26.00
  May 14, 2026
• MS

  Morgan Stanley on Pfizer (PFE): Atirmo Ph2 data an 'incremental positive'

  Morgan Stanley· Terence Flynn· $27.00
  Mar 17, 2026
• BC

  BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data

  BMO Capital· Evan David Seigerman· $30.00
  Mar 9, 2026
• RC

  RBC Capital Starts Pfizer (PFE) at Underperform

  RBC Capital· Trung Huynh· $25.00
  Feb 24, 2026